ArticleFrontiers in oncology2022

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy.

Ping Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.